�The Multiple Myeloma Research Consortium (MMRC) announced the initiation of a clinical trial with the unwritten immunomodulatory agent pomalidomide (CC-4047) in patients who have received at least two prior therapies including treatments with REVLIMID� (lenalidomide) and VELCADE� (bortezomib) for Injection.
Paul Richardson, MD, Clinical Director of the Jerome Lipper Center for Multiple Myeloma at Dana-Farber Cancer Institute, is leading the Phase 1 / 2, multicenter, randomized, open-label, dose-escalation study. The Phase 1 study is designed to determine maximum tolerated dose of single-agent pomalidomide piece the Phase 2 randomised study will compare the oral compound's efficacy alone against its combination with dexamethasone.
"This potent new immunomodulator, which is in the same class as thalidomide and lenalidomide, volition hopefully be successful in treating patients who have relapsed or who don't respond to currently usable treatment options. We are excited to be testing pomalidomide in this setting and are optimistic that it will meaningfully add to our therapeutic options for our patients," said Dr. Richardson.
"This fresh clinical tribulation brings the total figure of studies that the MMRC has initiated to fourteen. We are thrilled to advance this study in our mission to identify and prioritize the most bright treatments for patients with multiple myeloma", said Kathy Giusti, Founder and Chief Executive Officer of the MMRC, and a myeloma patient.
Pomalidomide is an IMiDs compound, a member of Celgene's proprietary mathematical group of novel oral immunomodulatory agents that impede or stabilize disease through respective mechanisms of action, including anti-angiogenic natural process.
Celgene's lead IMiDs compound, REVLIMID� (lenalidomide) continues to demonstrate unprecedented overall endurance in multiple myeloma as well as significant clinical potential across a broad range of blood cancers. To particular date, REVLIMID has obtained orphan drug identification for myelodysplastic syndrome in the European Union (EU), United States (US), and Australia, orphan drug assignment for multiple myeloma (MM) in the EU, US, Australia and Switzerland, and orphan do drugs designation for chronic lymphocytic leukemia (CLL) in the EU and US. REVLIMID is presently approved for use in the US and Canada for the treatment of patients with transfusion-dependent genus Anemia due to low- or intermediate-1-risk MDS associated with a deletion 5q cytogenetical abnormality with or without additional cytogenetic abnormalities. REVLIMID is likewise approved for use in the EU, US and Switzerland for the treatment of multiple myeloma in combination with dexamethasone in patients world Health Organization have standard at least one prior therapy, and Australia for patients with multiple myeloma whose disease has progressed after nonpareil therapy.
About IMiDs�
IMiDs compounds ar proprietary novel small molecule, orally uncommitted compounds that modulate the immune system and other biologically significant targets through multiple mechanisms of action, including angiogenesis inhibition, inflection of the levels of key pro-inflammatory and regulative cytokines and immune jail cell co-stimulation (eg, T cells, NK cells)
About Celgene
Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global biopharmaceutical company occupied primarily in the discovery, development and commercialization of novel therapies for the treatment of cancer and inflammatory diseases through factor and protein regulation. For more information, please chatter the Company's website at http://www.celgene.com.
About the Multiple Myeloma Research Consortium (MMRC)
The Multiple Myeloma Research Foundation (MMRC), a 509a3 organization, was founded in 2004 by Kathy Giusti, a myeloma patient and Founder and Chief Executive Officer of the Multiple Myeloma Research Foundation, to speed the development of novel and combination treatments for patients with multiple myeloma by facilitating innovative clinical trials and correlative studies.
At the core of the MMRC model is an surpassing Executive Committee, based in Norwalk, Conn., which provides strategic inadvertence of the MMRC's drug development projects. The MMRC's 15 Member Institutions ar among the prominent academic research centers worldwide: City of Hope, Dana-Farber Cancer Institute, Emory University's Winship Cancer Institute, the Cancer Center at Hackensack University Medical Center, H. Lee Moffitt Cancer Center & Research Institute, Indiana University, Mayo Clinic, Ohio State University, Roswell Park Cancer Institute, St. Vincent's Comprehensive Cancer Center of Saint Vincent Catholic Medical Centers of New York, University Health Network (Princess Margaret Hospital), University of Chicago, University of Michigan, University of California - San Francisco, and Washington University.
The MMRC model besides includes an advanced Tissue and Data Bank, which serve as a "bridge" between laboratory and clinical research conducted by the MMRC and a critical resource in advancing MMRC clinical trials and correlative science studies.
As a results-driven organization, the MMRC has facilitated to escort 15 Phase I and II clinical trials of the most promising novel compounds and combination approaches. MMRC clinical trials ar designed to include correlative studies to better infer what drugs are to the highest degree effective in treating several sub-groups of myeloma patients, laying the foundation for the eventual development of personalized medicines as a treatment for myeloma.
The Multiple Myeloma Research Consortium
View drug information on Revlimid; Velcade.
More information
Wednesday, 3 September 2008
Wednesday, 6 August 2008
California Communities Host Conferences To Discuss Cancer And Hispanics
�
Two communities in California will be addressing malignant neoplastic disease among Hispanics. Summaries of news coverage previewing the events appear below.
Santa Cruz County: A daylong assembly on Aug. 8, sponsored by the American Cancer Society, will address issues such as why malignant neoplastic disease rates and mortality from the disease are often higher for Hispanics
Two communities in California will be addressing malignant neoplastic disease among Hispanics. Summaries of news coverage previewing the events appear below.
Santa Cruz County: A daylong assembly on Aug. 8, sponsored by the American Cancer Society, will address issues such as why malignant neoplastic disease rates and mortality from the disease are often higher for Hispanics
Friday, 27 June 2008
John Tesh
Artist: John Tesh
Genre(s):
New Age
Instrumental
Discography:
Pure Hymns
Year: 2000
Tracks: 13
Forever More - The Greatest Hits Of John Tesh
Year: 2000
Tracks: 13
Pure Movies
Year: 1998
Tracks: 16
One World
Year: 1998
Tracks: 13
Grand Passion
Year: 1998
Tracks: 13
Victory The Sports Colection
Year: 1997
Tracks: 13
Avalon
Year: 1997
Tracks: 13
Discovery
Year: 1996
Tracks: 12
Sax On The Beach
Year: 1995
Tracks: 12
Sax By The Fire
Year: 1995
Tracks: 12
Live At Red Rocks
Year: 1995
Tracks: 16
Winter Song
Year: 1994
Tracks: 12
The Choirs Of Christmas
Year: 1994
Tracks: 12
The Games
Year: 1992
Tracks: 9
Ironman Triathalon
Year: 1992
Tracks: 9
A Romantic Christmas
Year: 1992
Tracks: 16
Garden City
Year: 1989
Tracks: 9
Tour De France
Year: 1988
Tracks: 7
Guitar By The Fire
Year:
Tracks: 13
For many years, John Tesh went near unrecognised as a instrumentalist and composer, rather enjoying television success as the co-host of the nightly showbiz news magazine Entertainment Tonight; while his initial attempts to mount a recording career were met with contempt and ridicule, he enjoyed the last laugh on his detractors, rising to become one of new historic period instrumental music's biggest superstars. Born July 9, 1952 in Long Island, New York, Tesh began acting piano at the age of six-spot; as a adolescent, he too played pipe organ and trombone with local sway bands. After graduating North Carolina State University with a degree in euphony and communication theory, Tesh worked at a patterned advance of telecasting stations of the Cross passim the southeastern U.S., later on graduating to the perspective of anchor at the CBS network's New York City affiliate. In 1981, he united CBS Sports as a commentator, where he later on won Emmy Awards for his Pan American Games radical and the motif to the Tour de France.
In 1986, Tesh left CBS to legion the syndicated Entertainment Tonight with co-anchor Mary Hart; piece telecasting remained his primary focus, he continued writing and performing music, and in 1988 issued his showtime record album, Turn de France. Critics panned his brand name of melodramatic, orchestral new long time music, merely the success of farther efforts including 1989's Garden City proven a ontogenesis audience existed for his work. In 1991, Tesh won some other couple of Emmys for his medicine for NBC Sports' insurance coverage of the World Track and Field Championships; a yr later on, he formed his have label, GTS, and issued Romanticistic Christmas, his biggest attain to engagement. Smashes including 1993's Monterey Nights and 1994's Adolphe Sax by the Fire followed, and in 1995 Tesh's PBS exceptional and record album Live at Red Rocks emerged as something of a phenomenon. He shortly left wing Entertainment Tonight to focus all of his energies on music, grading serial hits with the likes of 1996's Sax on the Beach and its 1997 followup, Adolphe Sax All Night. High-flown Passion followed in early 1998, trailed a year later by Unrivaled World and Gospel According to John Tesh & Friends. Pure Hymns was issued in fall 2000 and Pure Orchestra and Pure Gospel followed in early 2001.
Classical Music for Babies (And Their Moms), Vol. 2 appeared later on that springtime.
Thursday, 19 June 2008
Gotan Project
Artist: Gotan Project
Genre(s):
Latin
Tango
Electronic
Discography:
La Revancha del Tango Live
Year: 2007
Tracks: 16
Lunatico
Year: 2006
Tracks: 12
Inspiracion-Espiracion Remix (CD 2)
Year: 2004
Tracks: 1
La Revancha Del Tango
Year: 2001
Tracks: 10
Before they perfected the electronica-meets-tango sound of the Gotan Project, Paris musicians Philippe Cohen Solal and Christoph H. Mueller worked together in the Boys from Brazil and Stereo Action Unlimited as early as 1996. Releasing their music on Solal's Ya Basta label, the two apace caught the ears of Jazzanova, Gilles Peterson, Mr. Scruff, and other electronica tastemakers, piece Coca-Cola picked a Boys from Brazil running for a European idiot box commercial-grade. Despite all the success, the twosome treasured a project that had a more than changeless mood. Feeling that both tango and nickname had a subdued and melancholic sound, they distinct to combine the genres. With the plus of Eduardo Makaroff in 1999, they formed the Gotan Project and released the low of four 10"s on Ya Basta in February 2000. The band had drummed up quite a buzz in the U.K. and European press, and shortly XL recordings snagged the mathematical group. XL issued their uncut debut, La Revancha del Tango, in 2001, and the self-proclaimed "cover Argentinean musicians exiled in Paris" toured to support the album with guest musicians and a video recording backdrop by multimedia system artist Prisca Lobjoy. Lunatico from 2006 was named after tango fable Carlos Gardel's paladin race horse.
Sandy Nelson
Friday, 13 June 2008
Radical Attack
Artist: Radical Attack
Genre(s):
Other
Discography:
Summer Tour
Year: 2004
Tracks: 10
Gary Numan - Gary Numan To Play Mighty Boosh Festival
Saturday, 7 June 2008
Kelly Rowland plans to buy home in London
Kelly Rowland is planning to movie to England — and has been looking for properties in London’s posh Chelsea.
The ‘Work’ hitmaker was seen looking at homes all day Saturday before heading to the trendy Mamilanji bar on King’s Road in the evening.
Other big names to ditch the US for London include Gwen Stefani and Madonna.
A source said: “Kelly wanted to get a feel of the local nightlife.
See Also
Monday, 26 May 2008
Scarlett Johansson's album debut panned by critics
LOS ANGELES (Reuters) - Actress Scarlett Johansson's latest film work may be getting the red carpet treatment at Cannes, but her debut album, released on Tuesday, is drawing fire from music critics.
"Anywhere I Lay My Head," a collection of Tom Waits songs recorded by the star of such films as "Match Point," "Lost in Translation" and "Girl with a Pearl Earring," has been described by the actress as "an intimate experience."
But numerous reviews of the album complained that Johansson's vocals end up lost in the lush arrangements of producer David Andrew Sitek, the guitarist and keyboardist for the indie rock band TV on the Radio.
For some critics, that wasn't necessarily a bad thing.
"Johansson's voice is unremarkable and her pitch sometimes unsteady; she's a faintly goth Marilyn Manson lost in a sonic fog," wrote Rolling Stone magazine, which gave her a lukewarm 2.5 stars out of five.
Britain's Mojo magazine called the recordings "fussy and forgettable," adding that the decision to begin the album with an instrumental was hardly a vote of confidence in Johansson's vocal abilities.
The disc received a middling "C" grade from Entertainment Weekly magazine, which wrote that her "expressionless voice" was buried "deeply in the druggy ambiance."
And the Washington Post said it was possible to listen to all 40-plus minutes of Johansson's album and "still have no earthly idea what she sounds like."
"Anywhere I Lay My Head," a collection of Tom Waits songs recorded by the star of such films as "Match Point," "Lost in Translation" and "Girl with a Pearl Earring," has been described by the actress as "an intimate experience."
But numerous reviews of the album complained that Johansson's vocals end up lost in the lush arrangements of producer David Andrew Sitek, the guitarist and keyboardist for the indie rock band TV on the Radio.
For some critics, that wasn't necessarily a bad thing.
"Johansson's voice is unremarkable and her pitch sometimes unsteady; she's a faintly goth Marilyn Manson lost in a sonic fog," wrote Rolling Stone magazine, which gave her a lukewarm 2.5 stars out of five.
Britain's Mojo magazine called the recordings "fussy and forgettable," adding that the decision to begin the album with an instrumental was hardly a vote of confidence in Johansson's vocal abilities.
The disc received a middling "C" grade from Entertainment Weekly magazine, which wrote that her "expressionless voice" was buried "deeply in the druggy ambiance."
And the Washington Post said it was possible to listen to all 40-plus minutes of Johansson's album and "still have no earthly idea what she sounds like."
Subscribe to:
Posts (Atom)